Endocarditis screening: Difference between revisions
Created page with "__NOTOC__ {{Xyz}} {{CMG}}; {{AE}} ==Overview== There is insufficient evidence to recommend routine screening for [disease/malignancy]. OR According to the [guideline nam..." |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Endocarditis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} |
Revision as of 16:27, 18 December 2019
Endocarditis Microchapters |
Diagnosis |
---|
Treatment |
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
Case Studies |
Endocarditis screening On the Web |
Risk calculators and risk factors for Endocarditis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]